Government-Owned Inventions; Availability for Licensing, 35686-35687 [05-12130]
Download as PDF
<![CDATA[
35686
Federal Register / Vol. 70, No. 118 / Tuesday, June 21, 2005 / Notices
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact: Dr.
Christine D. Berg, Chief, Early Detection
Research Group, National Cancer
Institute, NIH, EPN Building, Room
3070, 6130 Executive Boulevard,
Bethesda, MD 20892, or call non-tollfree number 301–496–8544 or e-mail
your request, including your address to:
Bergc@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
Dated: June 10, 2005.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 05–12128 Filed 6–20–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Epitopes of Ebola Virus Glycoproteins
Useful for Vaccine Development
Carolyn A. Wilson et al. (FDA)
U.S. Provisional Application No. 60/
532,677 filed 23 Dec 2003 (DHHS
Reference No. E–271–2003/0–US–01);
VerDate jul<14>2003
22:07 Jun 20, 2005
Jkt 205001
PCT Patent Application filed 23 Dec
2004 (DHHS Reference No. E–271–
2003/1–PCT–01).
Licensing Contact: Susan Ano; 301/435–
5515; anos@mail.nih.gov.
The current technology relates to the
identification of two highly conserved
linear domains of Ebola or Marburg
envelope glycoprotein (GP) and of
amino acid residues within these
regions critical for virus infection. The
identified domains could provide
targets for rational design and
development of broadly cross-protective
antivirals and vaccines. There are
currently no licensed vaccines against
Ebola and Marburg. The linear domains
(or portions) could potentially be used
as immunogens in a vaccine. Mutations
containing these epitopes have been
identified to result in the formation of
non-infectious Ebola viral particles,
which could be useful for developing
vaccines against Ebola virus, a category
A biodefense agent. Vaccines utilizing
these non-infectious particles may be
safer than vaccines that use other
common approaches, e.g. liveattenuated virus vaccines. This
technology describes the polypeptides
that form the non-infectious Ebola viral
particles, the polynucleotide sequences
encoding the polypeptides, vectors
comprising the polynucleotides, host
cells transformed with such vectors,
vaccines and methods suitable for use in
the prevention and/or treatment of
hemorrhagic fever due to Ebola or
Marburg, and a molecular decoy
comprising the polynucleotides. These
additional materials could also form the
basis of an Ebola vaccine or antiviral
therapy. Diagnostic applications
involving the aforementioned materials
are also described. Development of
antiviral compounds and vaccines for
treatment and prevention of Ebola and
Marburg infections would be of
tremendous benefit for biodefense and
public health. However, the current
Ebola vaccine technologies such as
DNA-based vaccines and subunit
vaccines either have safety risks or lack
broad cross-protectivity. Therefore, the
present technology could provide a
promising technology to make safe and
broad cross-reactive antivirals or
vaccines against Ebola and Marburg
viruses.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Detection and Identification of
Mycobacterium Using SecA
Steven H. Fischer and Adrian M.
Zelazny (CC)
U.S. Provisional Application No. 60/
548,371 filed 27 Feb 2004 (DHHS Ref.
No. E–238–2003/0–US–01); PCT
Application No. PCT/US05/06609
filed 28 Feb 2005 (DHHS Ref. No. E–
238–2003/0–PCT–02).
Licensing Contact: Robert M. Joynes,
J.D.; 301/594–6565;
joynesr@mail.nih.gov.
This invention relates to a method of
detecting a wide variety of
Mycobacterium and Nocardia species in
a sample. The method involves
hybridizing an amplified
Mycobacterium/Nocardia genus-specific
secA nucleic acid to a Mycobacterium/
Nocardia species-specific secA probe
oligonucleotide, wherein the
amplification utilizes at least two
Mycobacterium/Nocardia genus-specific
primers, and detecting hybridization of
the Mycobacterium/Nocardia-specific
secA nucleic acid. The Mycobacterium/
Nocardia genus-specific primers bind
within a conserved region of the nucleic
acid sequence encoding a
Mycobacterium/Nocardia bi-genusspecific secA protein, wherein the
conserved region is in the 5’ half of the
Mycobacterium/Nocardia secA gene and
includes a substrate specificity domain.
The approach for detection of
Mycobacterium/Nocardia species in
clinical materials could potentially be
used as a universal system for detection
of any member of the genus
Mycobacterium and the genus Nocardia
and identification at the species or
complex level. The system currently
identifies all mycobacteria tested to
date. With a few modifications, we
believe it will also detect all Nocardia
species of clinical significance. Contrary
to commercial methods based on 16S
rRNA and ITS, the SecA method will
detect both Mycobacterium and
Nocardia species. The region targeted
has sufficient sequence variation for
discrimination at the species or complex
level.
Based on the information available to
date, the SecA approach could be
potentially used to replace acid-fast
smears (AFB) and modified acid-fast
smears, could provide definitive
detection and identification of a large
variety of Mycobacterium and Nocardia
species present in clinical materials,
and could be used as a single
confirmation and species identification
system for suspected positive
Mycobacterium or Nocardia cultures.
The invention also contemplates
devices, including arrays, and kits for
E:\FR\FM\21JNN1.SGM
21JNN1
Federal Register / Vol. 70, No. 118 / Tuesday, June 21, 2005 / Notices
detecting Mycobacterium or Nocardia
species in a sample.
This technology is related to Dr.
Fischer’s other technology, E–278–1999/
0, ‘‘Multiplex Hybridization System for
the Identification of Pathogenic
Mycobacterium and Method of Use’’
(published in the Federal Register on
September 7, 2002, 65 FR 54288). The
distinguishing feature in the current
invention that makes it a vast
improvement over E–278–1999/0 is the
ability to detect all 29 Mycobacterium
species tested to date and potentially all
Nocardia species in a clinical sample.
Cloned Genomes of Infectious Hepatitis
C Virus and Uses Thereof
Masayuki Yanagi, Jens Bukh, Suzanne
U. Emerson, Robert H. Purcell (NIAID)
U.S. Patent No. 6,153,421 issued on 28
Nov 2000 (DHHS Reference No. E–
050–1998/0–US–01); U.S. Patent
Application No. 09/662,454 filed 14
Sep 2000 (DHHS Reference No. E–
050–1998/0–US–03); Canadian
Application 2295552; Australian
Application 84889/98; European
Application 98935702.5.
Licensing Contact: Chekesha S.
Clingman; 301/435–5018;
clingmac@mail.nih.gov.
The current invention provides
nucleic acid sequences comprising the
genomes of infectious hepatitis C
viruses (HCV) of genotype 1a and 1b. It
covers the use of these sequences, and
polypeptides encoded by all or part of
the sequences, in the development of
vaccines and diagnostic assays for HCV
and the development of screening
assays for the identification of antiviral
agents for HCV.
Additional information can be found
in: Yanagi et al., ‘‘Transcripts from a
single full-length cDNA clone of
hepatitis C virus are infectious when
directly transfected into the liver of a
chimpanzee,’’ Proc. Natl. Acad. Sci.
USA (1997 August) 94(16):8738–8743;
and Yanagi et al., ‘‘Transcripts of a
chimeric cDNA clone of hepatitis C
virus genotype 1b are infectious in
vivo,’’ Virology (25 April 1998)
244(1):161–172.
Dated: June 6, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–12130 Filed 6–20–05; 8:45 am]
BILLING CODE 4140–01–P
VerDate jul<14>2003
22:07 Jun 20, 2005
Jkt 205001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences 2006 Strategic Plan
National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health
(NIH), Department of Health and Human
Services (DHHS).
ACTION: Request for comments and
nominations.
AGENCY:
SUMMARY: The NIEHS is updating its
2000 strategic plan entitled NIEHS
Strategic Plan 2000—A Five-Year
Program: New Opportunities in
Environmental Health Research. To
anticipate, meet, and set priorities for
environmental health research, training,
resources, and technologies, NIEHS
requests input from scientists, members
of the public, and all interested parties.
The goal of this strategic planning
process is to identify barriers to progress
for future research and to define future
needs and directions for environmental
health. In addition, the NIEHS seeks the
nomination of individuals qualified to
participate in a workshop to discuss the
plan in more detail. The existing NIEHS
strategic plan can be viewed at https://
www.niehs.nih.gov/external/plan2000/
home.htm.
DATES: Submit responses to the NIEHS
Office of Science Policy and Planning,
(see below), on or before August 5, 2005.
ADDRESSES: The Office of Science Policy
and Planning, NIEHS/NIH, PO Box
12233, Research Triangle Park, NC
27709, telephone (919) 541–3484, FAX
(919) 541–1994, e-mail niehsplan2006@niehs.nih.gov. Comments
may be submitted electronically at the
NIEHS Strategic Planning Web site:
https://www.niehs.nih.gov/external/
plan2006/home.htm. They can also be
submitted by e-mail, mail or fax to the
above address.
SUPPLEMENTARY INFORMATION:
Background
The mission of the NIEHS is to reduce
the burden of environmentallyassociated disease and dysfunction by
defining three elements: (1) How
environmental exposures affect our
health, (2) how individuals differ in
their susceptibility to these exposures,
and (3) how these susceptibilities
change over time.
The NIEHS achieves its mission
through multidisciplinary biomedical
research programs and prevention and
intervention efforts. The NIEHS also
focuses on communication strategies
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
35687
that encompass training, education,
technology transfer, and community
outreach. Research is required to
disseminate evidence-based
environmental health policies that
prevent diseases.
Request for Comments
To ensure the continued relevance of
its Strategic Plan, the NIEHS seeks input
to the following questions relative to the
issues described above:
(A) What are the disease processes
and public health concerns that are
relevant to environmental health
sciences?
(B) How can environmental health
sciences be used to understand how
biological systems work, why some
individuals are more susceptible to
disease, or why individuals with the
same disease may have very different
clinical outcomes?
(C) What are the major opportunities
and challenges in global environmental
health?
(D) What are the environmental
exposures that need further
consideration?
(E) What are the critical needs for
training the next generation of scientists
in environmental health?
(F) What technology and
infrastructural changes are needed to
fundamentally advance environmental
health science?
Individuals submitting public
comments are asked to include relevant
contact information [name, affiliation (if
any), address, telephone, fax, e-mail,
and sponsoring organization, if
applicable].
Request for Nomination of Planning
Group Members
The NIEHS solicits nominations for
individuals to participate in a workshop
to discuss the plan in more detail.
Nominations should include the name,
degree(s), position title, department,
institution name and address, phone
and fax numbers, e-mail address, and
specific area of expertise. Information of
nominated individuals should be sent
by August 5, 2005 to the NIEHS office
of Science Policy and Planning (contact
information provided above).
Dated: June 8, 2005.
David A. Schwartz,
Director, National Institute of Environmental
Health Sciences.
[FR Doc. 05–12129 Filed 6–20–05; 8:45 am]
BILLING CODE 4167–01–P
E:\FR\FM\21JNN1.SGM
21JNN1
]]>Agencies
[Federal Register Volume 70, Number 118 (Tuesday, June 21, 2005)]
[Notices]
[Pages 35686-35687]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-12130]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Epitopes of Ebola Virus Glycoproteins Useful for Vaccine Development
Carolyn A. Wilson et al. (FDA)
U.S. Provisional Application No. 60/532,677 filed 23 Dec 2003 (DHHS
Reference No. E-271-2003/0-US-01); PCT Patent Application filed 23 Dec
2004 (DHHS Reference No. E-271-2003/1-PCT-01).
Licensing Contact: Susan Ano; 301/435-5515; anos@mail.nih.gov.
The current technology relates to the identification of two highly
conserved linear domains of Ebola or Marburg envelope glycoprotein (GP)
and of amino acid residues within these regions critical for virus
infection. The identified domains could provide targets for rational
design and development of broadly cross-protective antivirals and
vaccines. There are currently no licensed vaccines against Ebola and
Marburg. The linear domains (or portions) could potentially be used as
immunogens in a vaccine. Mutations containing these epitopes have been
identified to result in the formation of non-infectious Ebola viral
particles, which could be useful for developing vaccines against Ebola
virus, a category A biodefense agent. Vaccines utilizing these non-
infectious particles may be safer than vaccines that use other common
approaches, e.g. live-attenuated virus vaccines. This technology
describes the polypeptides that form the non-infectious Ebola viral
particles, the polynucleotide sequences encoding the polypeptides,
vectors comprising the polynucleotides, host cells transformed with
such vectors, vaccines and methods suitable for use in the prevention
and/or treatment of hemorrhagic fever due to Ebola or Marburg, and a
molecular decoy comprising the polynucleotides. These additional
materials could also form the basis of an Ebola vaccine or antiviral
therapy. Diagnostic applications involving the aforementioned materials
are also described. Development of antiviral compounds and vaccines for
treatment and prevention of Ebola and Marburg infections would be of
tremendous benefit for biodefense and public health. However, the
current Ebola vaccine technologies such as DNA-based vaccines and
subunit vaccines either have safety risks or lack broad cross-
protectivity. Therefore, the present technology could provide a
promising technology to make safe and broad cross-reactive antivirals
or vaccines against Ebola and Marburg viruses.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Detection and Identification of Mycobacterium Using SecA
Steven H. Fischer and Adrian M. Zelazny (CC)
U.S. Provisional Application No. 60/548,371 filed 27 Feb 2004 (DHHS
Ref. No. E-238-2003/0-US-01); PCT Application No. PCT/US05/06609 filed
28 Feb 2005 (DHHS Ref. No. E-238-2003/0-PCT-02).
Licensing Contact: Robert M. Joynes, J.D.; 301/594-6565;
joynesr@mail.nih.gov.
This invention relates to a method of detecting a wide variety of
Mycobacterium and Nocardia species in a sample. The method involves
hybridizing an amplified Mycobacterium/Nocardia genus-specific secA
nucleic acid to a Mycobacterium/Nocardia species-specific secA probe
oligonucleotide, wherein the amplification utilizes at least two
Mycobacterium/Nocardia genus-specific primers, and detecting
hybridization of the Mycobacterium/Nocardia-specific secA nucleic acid.
The Mycobacterium/Nocardia genus-specific primers bind within a
conserved region of the nucleic acid sequence encoding a Mycobacterium/
Nocardia bi-genus-specific secA protein, wherein the conserved region
is in the 5' half of the Mycobacterium/Nocardia secA gene and includes
a substrate specificity domain.
The approach for detection of Mycobacterium/Nocardia species in
clinical materials could potentially be used as a universal system for
detection of any member of the genus Mycobacterium and the genus
Nocardia and identification at the species or complex level. The system
currently identifies all mycobacteria tested to date. With a few
modifications, we believe it will also detect all Nocardia species of
clinical significance. Contrary to commercial methods based on 16S rRNA
and ITS, the SecA method will detect both Mycobacterium and Nocardia
species. The region targeted has sufficient sequence variation for
discrimination at the species or complex level.
Based on the information available to date, the SecA approach could
be potentially used to replace acid-fast smears (AFB) and modified
acid-fast smears, could provide definitive detection and identification
of a large variety of Mycobacterium and Nocardia species present in
clinical materials, and could be used as a single confirmation and
species identification system for suspected positive Mycobacterium or
Nocardia cultures. The invention also contemplates devices, including
arrays, and kits for
[[Page 35687]]
detecting Mycobacterium or Nocardia species in a sample.
This technology is related to Dr. Fischer's other technology, E-
278-1999/0, ``Multiplex Hybridization System for the Identification of
Pathogenic Mycobacterium and Method of Use'' (published in the Federal
Register on September 7, 2002, 65 FR 54288). The distinguishing feature
in the current invention that makes it a vast improvement over E-278-
1999/0 is the ability to detect all 29 Mycobacterium species tested to
date and potentially all Nocardia species in a clinical sample.
Cloned Genomes of Infectious Hepatitis C Virus and Uses Thereof
Masayuki Yanagi, Jens Bukh, Suzanne U. Emerson, Robert H. Purcell
(NIAID)
U.S. Patent No. 6,153,421 issued on 28 Nov 2000 (DHHS Reference No. E-
050-1998/0-US-01); U.S. Patent Application No. 09/662,454 filed 14 Sep
2000 (DHHS Reference No. E-050-1998/0-US-03); Canadian Application
2295552; Australian Application 84889/98; European Application
98935702.5.
Licensing Contact: Chekesha S. Clingman; 301/435-5018;
clingmac@mail.nih.gov.
The current invention provides nucleic acid sequences comprising
the genomes of infectious hepatitis C viruses (HCV) of genotype 1a and
1b. It covers the use of these sequences, and polypeptides encoded by
all or part of the sequences, in the development of vaccines and
diagnostic assays for HCV and the development of screening assays for
the identification of antiviral agents for HCV.
Additional information can be found in: Yanagi et al.,
``Transcripts from a single full-length cDNA clone of hepatitis C virus
are infectious when directly transfected into the liver of a
chimpanzee,'' Proc. Natl. Acad. Sci. USA (1997 August) 94(16):8738-
8743; and Yanagi et al., ``Transcripts of a chimeric cDNA clone of
hepatitis C virus genotype 1b are infectious in vivo,'' Virology (25
April 1998) 244(1):161-172.
Dated: June 6, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-12130 Filed 6-20-05; 8:45 am]
BILLING CODE 4140-01-P
